Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 8905 results

  1. Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg [TSID11894]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 [TSID10767]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Aflibercept for untreated diabetic macular oedema [TSID10621]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Teduglutide for treating short bowel syndrome in babies 4 to 12 months [TSID10755]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Aflibercept for untreated retinopathy in babies born preterm TS ID 11943

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Mepolizumab for treating chronic obstructive pulmonary disease with eosinophil-associated exacerbations TSID12019

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Lenacapavir for treating multidrug resistant HIV-1 [ID6196]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation